80 likes | 193 Views
Overhauling company profiles introducing strategic data on M&A, early R&D in reverse chronological order. Project includes meeting timeliness and action term indexing. Enhancements include drug data, targets, patent challenges, regulatory data, and more.
E N D
Overhaul of company profiles Fielding (location, M&A, early R&D) Reverse chronological order Ongoing but complete for >2500 companies
Meeting report timeliness* 2004: 19.5 days 2005: 15.0 days 2006: 14 days (target) *days to publication for commissioned reports
Action term indexing 2000: 1800 terms 2006: >13,000 terms plus similar # of synonyms Ongoing project - ~100 new terms per week
Launched drug data Strategic drug data (SWOT analyses, sales commentaries, concensus forecasts) DRUGDEX (overview, dosing, toxicity, FDA approvals) Medstat (Prescription profiling)
Targets As of 9 June 06, 3709 targets mapped to existing action terms 85% Swiss-Prot validated
Generic competition data API manufacturing changes (capability, inspections) Patent challenges (paragraph IV) ANDAs – tentative, approved (and discontinued NDAs) SPCs Orange book data
Regulatory data FDA Advisory Committee reports New regulatory texts Regulatory alert Regulatory webcasts Regional regulatory reports